

## **Remarks**

By this amendment, claims 1-33 and 37-97 of the application have been cancelled and new claims 98-114 have been added to the application.

New claims 98-102 are directed to a composition comprising a cocktail of recombinant or synthetic antigens derived from hookworm, which may contain at least one larval stage antigen and at least one adult stage. Specific examples of antigens are recited. Support for these new claims may be found in the specification, for example, at page 22, lines 17-31.

New claims 103-109 are directed to a method of vaccinating or eliciting an immune response to hookworm in a mammal by administering a composition comprising a recombinant or synthetic antigen derived from hookworm, for example in a cocktail of recombinant or synthetic antigens. Support for these claims can be found in the specification, for example, at page 23, lines 1-2.

New claim 110-116 recite a method of reducing blood loss in a patient infected with hookworm by administering a composition comprising a recombinant or synthetic antigen derived from hookworm, for example in a cocktail of recombinant or synthetic antigens. Support for these claims can be found in the specification at, for example, page 23, lines 30-31.

New claims 117-123 recite a method of reducing hookworm size, quantitative egg count, or hookworm burden by administering a composition comprising a recombinant or synthetic antigen derived from hookworm, for example in a cocktail of recombinant or synthetic antigens. Support for these new claims is found in the specification, for example, at page 69, line 57 and page 89, line 9.

New claims 124-132 recite a method of decreasing L3 migration across the skin of a mammal by administering a composition comprising a recombinant or synthetic antigen derived from hookworm, for example in a cocktail of recombinant or synthetic antigens. Support for these new claims is found in the specification, for example, at page 89, lines 14-15.

Applicant submits that these new claims thus do not go beyond the disclosure of the application.

### **Formal Matters and Conclusion**

The Examiner is respectfully requested to examine and pass the above application to issue at the earliest possible time.

Should the Examiner find the application to be other than in condition for allowance, the Examiner is requested to contact the undersigned at the local telephone number listed below to discuss any other changes deemed necessary in a telephonic or personal interview.

Please charge any underpayment or credit any overpayment of fees to attorney's deposit account #50-2041.

Respectfully submitted,



Ruth E. Tyler-Cross

Reg. No. 45,922

Whitham, Curtis & Christofferson  
11491 Sunset Hills Road; Suite 340  
Reston, VA 20190  
703-787-9400